Pelgraz

RSS

pegfilgrastim

Authorised
This medicine is authorised for use in the European Union.

Overview

Pelgraz is a medicine used in cancer patients to help with neutropenia (low levels of neutrophils, a type of white blood cell), which is a common side effect of cancer treatment and can leave patients vulnerable to infections.

It is given specifically to reduce the duration of neutropenia and prevent febrile neutropenia (when neutropenia is accompanied by fever).

Pelgraz is not intended for use in patients with the blood cancer chronic myeloid leukaemia or with myelodysplastic syndromes (conditions in which large numbers of abnormal blood cells are produced, , which can develop into leukaemia).

Pelgraz is a ‘biosimilar medicine’. This means that Pelgraz is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Pelgraz is Neulasta.

This EPAR was last updated on 05/12/2018

Authorisation details

Product details
Name
Pelgraz
Agency product number
EMEA/H/C/003961
Active substance
pegfilgrastim
International non-proprietary name (INN) or common name
pegfilgrastim
Therapeutic area (MeSH)
Neutropenia
Anatomical therapeutic chemical (ATC) code
L03AA13
Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the ‘reference medicine’. For more information, see Biosimilar medicines.

Publication details
Marketing-authorisation holder
Accord Healthcare Limited
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
20/09/2018
Contact address

Sage House
319 Pinner Road
North Harrow
Middlesex HA1 4HF
United Kingdom

Product information

06/11/2018 Pelgraz - EMEA/H/C/003961 - IAIN/0001/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunostimulants

Therapeutic indication

Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Assessment history

How useful was this page?

Add your rating